Review3 Biotech2024
Revisiting microbial exopolysaccharides: a biocompatible and sustainable polymeric material for multifaceted biomedical applications.
Review in 3 Biotech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Physicochemical and Functional Characterization of a Novel Extremophilic Exopolysaccharide Produced byMicroorganisms · 2026Article
- Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial exopolysaccharides (EPS) have gained significant attention as versatile biomolecules with multifarious applications across various sectors. This review explores the valorisation of EPS and its potential impact on diverse sectors, including food, pharmaceuticals, cosmetics, and biotechnology. EPS, secreted by microorganisms, possess unique physicochemical properties, such as high molecular weight, water solubility, and biocompatibility, making them attractive for numerous functional roles. Additionally, EPS exhibit significant bioactivity, contributing to their potential use in pharmaceuticals for drug delivery and tissue engineering applications. Moreover, the eco-friendly and sustainable nature of microbial EPS production aligns with the growing demand for environmentally conscious processes. However, challenges still exist in large-scale production, purification, and regulatory approval for commercial use. Advances in bioprocessing and microbial engineering offer promising solutions to overcome these hurdles. Stringent investigations have concluded EPS as novel sources for sustainable applications that are likely to emerge and develop, further reinforcing the significance of these biopolymers in addressing contemporary societal needs and driving innovation in various industrial sectors. Overall, the microbial EPS represents a thriving field with immense potential for meeting diverse industrial demands and advancing sustainable technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.